BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ABSK112 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ABSK112\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06225804-2325@assetmemo.bio
DTSTAMP:20261121T005441Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:ABSK112: Phase 1 readout est. (NCT06225804)
DESCRIPTION:ABSK112\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A Study
  to Assess Safety\, Tolerability\, and Pharmacokinetics of ABSK112 in Pati
 ents With Non-Small Cell Lung Cancer\nEstimated primary completion: March 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/absk112#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06225804
URL:https://assetmemo.bio/drug/absk112#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
